AAIC 2023 – Lilly downplays tau testing needs
But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.
Stock market strife subsides in second quarter
But large gains for some big pharma players flatter the overall figures.
Go or no go? Decision day looms for Eisai and Biogen
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
Leqembi heads towards full approval
Big questions now include details about a US registry and its impact on initial sales.
Quanterix sees a bright future for blood biomarkers
A new dawn breaks for blood tests in neurological diseases, though future data remain important.
Go or no go? Key FDA decisions for Argenx and Regeneron
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Donanemab delivers for Lilly
Pivotal data on the Alzheimer’s project beat expectations, raising hopes for a swift reimbursement U-turn.